CD163 and glioblastoma: From an immunological point of view, GBM is characterized by a immunosuppressive microenvironment [11]; even though the numbers of T-cells are typically normal among patients, an immunosuppressive population of CD163+ M2-like tumor-associated macrophages (M2-like TAMs) tends to be prevalent [12], spurring recent interest in this population as a possible target for novel strategies in immunotherapy.